Appl. No. 10/519,855 Amdt. dated: April 7, 2008 Reply to Office Action of: January 9, 2008

Amendments to the Drawings:

Please replace sheets 1-3 of the drawings with attached Replacements Sheets 1-5.

REMARKS/ARGUMENTS

This application has been carefully reviewed in light of the Office Action dated January 9, 2008. By way of this amendment, new claims 8-11 have been added, and claims 1-7 have been canceled. Sheets 1-3 of the drawings have been replaced with Replacement Sheets 1-5. The specification has been amended to include missing Table 1 and Table 2 as provided on Incorporated Sheets 1-5.

All Incorporated Sheets claim incorporation to PCT/JP03/08305 and WO 2004/003021 as required by MPEP ∮ 1.57, and an English translated copy of the priority document is provided as United States Patent Publication No. 2006/0292160. Replacement Sheets 2 and 4 also claim incorporation to PCT/JP03/08305 and WO 2004/003021 as required by MPEP ∮ 1.57, and an English translated copy of the priority document is provided as United States Patent Publication No. 2006/0292160.

The specification was objected to under the provisions set forth by 37 C.F.R. ∮ 1.821-1.825 for failing to identify sequences in the specification and/or drawings with a sequence identifier. Replacement Sheets 1-5 and Incorporated Sheets 1-5 have been added to further identify the sequence listings.

Objections to the Specification

The specification was objected to because Tables 1 and 2 were listed but not provided. Incorporated Sheets 1-5 are provided to address this objection and show missing

The disclosure referenced five figures, while only three appeared in the application.

Replacement Sheets 2 and 4 are provided to amend the drawings to include the missing figures. The inadvertently omitted portion of the drawings can be found on sheets 3 and

sheet 5 of the translated application. United States Patent Publication No. 2006/0292160.

The drawings were also objected to for failing to include a figure designation.

Replacement Sheets 1, 3, and 5 are provided in response to the Examiner's rejection that the figures did not include a figure designation.

Rejections under 35 U.S.C. ∮ 112, Second Paragraph

Claims 1-7 are rejected under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claims 1-6 have been cancelled in light of this rejection.

Rejections under 35 U.S.C. ∮ 112, First Paragraph

Claims 4-7 are rejected under 35 U.S.C. § 112, first paragraph for failing to provide an enabling disclosure for the claimed invention. Claims 1, 4, and 5 are rejected for containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. Claims 2-5 are rejected because the claims contain subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. Claims 1-7 have been cancelled in light of this rejection.

Appl. No. 10/519,855 Amdt. dated: April 7, 2008 Reply to Office Action of: January 9, 2008

The present invention is directed to a monoclonal antibody falling within the category of human IgM which specifically recognizes HIV-infected cells and induces apoptosis. Using the obtained antibody, it is intended to provide a remedy for patients suffering from HIV-infection, which contains as the active ingredient a human IgM antibody capable of specifically reacting with HIV-infected cells, inducing apoptosis in the infected cells and thus disrupting the cells.

In response to the Examiner's rejections, new claims 8-11 are presented. Claim 8 provides a human IgM monoclonal antibody specifically recognizing HIV-infected cells and including apoptosis of the infected cells, said antibody denominated 2G9 antibody obtainable by a cell strain with an accession No.FERM BP-8378, and comprising sequence a H-chain variable region encoded by the base sequence SEQ ID No.1 and a L-chain variable region encoded by the base sequence SEQ ID No.2. Support for the newly added claims can be found in at least Fig. 1, which shows that the HIV-infected cells are recognized, Fig. 3, which shows that apoptosis is introduced into the HIV-infected cells, the accession number as indicated in the paragraph beginning on page 6, line 3, and SEQ ID Nos. 1 and 2 as indicated in the sequence listing filed with the USPTO on September 14, 2005.

The cell has also been deposited in the International Patent Organism Depository (IPOD) in Japan and is available through accession No. FERM BP-8378. The IPOD complies with the terms of the Budapest treaty, and all restrictions imposed by the

Appl. No. 10/519,855 Amdt. dated: April 7, 2008

Reply to Office Action of: January 9, 2008

depositor on the availability to the public of the deposited material will be irrevocably removed upon the granting of a patent.

The Director is hereby authorized to charge any additional fees or any underpayments which may be required for the above-referenced application to Deposit Account No. 01-0265.

Respectfully submitted,

/Thomas D. McClure, Jr./

Thomas D. McClure, Jr. Attorney for Applicant Reg. No. 54,302

Thomas D. McClure, Jr.
ADAMS INTELLECTUAL PROPERTY LAW, P.A.
Suite 2350

201 South College Street

Charlotte, NC 28244 Tel: (704) 375-9249

Fax: (704) 375-0729

Email: tdm@adamspat.com

File No.: 3348/1

TABLE 1

Base Sequence of µ-Chain Variable Region

TGCCCTGGATTCCAAGGCCTATCCACTTGGTGATCAGCACTGAGCACCGAGG
ATTCACCATGGAACTGGGGCTCCGCTGGGTTTTCCTTGTTGCTATTTTAGAA
GGTGTCCAGTGTGAGGTGCAGCTGGTGGAGTCTGGGGGAGGCCTGGTCAAG
CCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTA
CTTATAGCATGAACTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGG
TCCATCCATTAGTAGTAGTAGTAGTTACATATACTACGCAGACTCAGTGAA
GGGCCGATTCACCATCTCCAGAGACAACGCCAAGAACTCACTGTATCTGCAA
ATGAACAGCCTGAGGCCGAGGACACGCCTGTTATTACTGTGCGAGAGAT
CTCCTTATAGCAGTGGCTGGCCACTGGGCCCAGGGAACCCTGGTCACCGTCT
CCTCA

Base Sequence of K-Chain Variable Region

CTCAGTCAGGACACAGCATGGACATGAGGGTCCCTGCTCAGCTCCTGGGACT
CCTGCTGCTCTGGCTCCCAGATACCAGATGTGACATCCAGATGACCCAGTCT
CCATCCTCCCTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGCCGGG
CGAGTCAGGGCATTAGCAATTATTTAGCCTGGTATCAGCAGAAACCAGGGAA
AGTTCCTAAACTCCTGATCTATGCTGCATCCACTTTGCAATCAGGGGTCCCA
TCTCGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCA
GCCTGCAGCCTGAAGATGTTGCAACTTATTACTGTCAAAAGTATAACAGTGC
CCCGTACACTTTTGGCCAGGGGACCAAGCTGGAGATCAAA

Incorporated Sheet

TABLE 2: Examples of cDNA encoding equivalent amino acids in the amino acid sequences of 2G9 antibody

											-					
	. 4	NG.							6 0.	£.	g	ჟ.	g	CTA AGT	CTG AGC	
o	£.	ŭ								T K	Ĕ	- 51	ņ	CITY.	5176	
	ě	ă							,3	Į.	Į.	5	ũ	-	_	
a	ಶ	ð	4	Œ					, pe	8	ဦ	00	ñ	5	10	
۵	g	e de	GGA GTA	gge ere					4	T.	MG	f	S.	AGT CTA	Age era	
Α. 9	464	9	ĝ	ğ					α,	5	g	cca gga gga tca ctt cga ctt fca	ودو ووو هوو عدم خياد دوم حياد عاده	P.	AG	
M	37.5	25		•	_	_		٠.	ø.	63	90	ş	9			
ы	4	P	CIT	CIC	CTA	£			9	110	ည	5	98			
н	22	20.0							rs.	6	ŭ	ð	9			
es.	*	Ř	đ	g		•				<u>ت</u>	S	ō	ŏ			
	10	S S	5	9					M	2	2		130			
Þ	5	Š	CTT GTA GCA	cre era aca	5	o,			>	5	6TC	12	Đ.	_	•	
1	2	Į.	E	g.	E	Ď,	٠.		a	13	17.0	t	STO	ŧ	Ď.	
D ₄	111	TIC							O	364	ğ	5	908			
Þ	GIL	GTC.	OTA	010						5	29	TCA GGA GGA CTT GTA	זיכים סימים פופים פיטים פיזים פיזים	٠.		
32	Ş	99							ø	1.5	ပ္မ	5	ğ			
×	£.0	ñ	CTT GGA CTT CGA.	g					63	ij	b D	5	9	AGT	AGC	
H	₹.	Ď	. £	ည	CT.	GTC CTC			м	4	Ď.	Ē.	ě.	Ř	Ā	
	H	4	ĕ	ĝi B	გ.	ij			14	6	5					
Ф	9	8	8	حدد هوه جدد دهو					*	10	QTC	GE)	5			
4	Į.	TTG	Ę	£	CEA	S.			a	FTA	3	CTT GEA	CTC GRG	CTS	S.	
ы	ata gar tta ggt tta cgt 40a gtv ttv fta gtp ggt att tta gaa ggt gtt caa dgt gaa	ats gar ttg ggc ttg cgc tgg gtc ttc ctc gcc atc ttg gac gcc atc ttg							œ	itt caa fta get gaa het get get get tea get aar egt get bet tei tea est eer eer	וידיך כאק. ידים קורם פאס ויספ פסב פסב פסר וידים פוזר אאם מכר פסר ויביר וידים כפר יידים ויכר	٠.	7	•	J	
×	4	5						31	>	£	ò	T.	T.G			
	•	~						**		6	53	볐	딾			

p.	. 8	; ;	S	. 8					ځ ≽	Ų	} {	ş ş		
~	igt oct get tet ggt ttt let fitt tet let trt fet lia lit fit get est get est get elt	ישה שכם מכם דבה פשה דדם אמה ידה דפט אסת האם דכט אדש אאם דשה טבר כמם כאם שכם ככם	GCA CCA	800 000		·			ggt aaa ggt uta gaa bea beu nce art tct tct tct fct fct tat art eat eat	GGG ANG GGC TING GAG TAG GTC TCC ATC TCC TCC TCC TCC TCC TCC TAC ATC TAC TA				
o.	. 5	ŏ	. *					, :		Š				
at	G e	ð	*	b				,	4 E	5				
	8	ő	OTA CGA	GTG CGG				,	, ří	. d				
۵	5	- 5	5	5		•			2	7.	. 5		£	ŭ
æ	. 8	2						e,	ှုမို့	- ģ	2	19	*	, E
×	L	5						0)	i ji	ğ	ğ	ğ	8	ō
Ð	4	10						. 🜣	Ę	700	Đ,	Į,	5	¥.
C)	Č.	ខ្ល	Į,	TO S	AGT	AGC		63	TC.	. 22	Ş	300	agt agt agt agt agt	AGC AGC AGC AGC AGC
	44	Ď.						. 00	FCT	ğ	TCA PGA TCA TCA TCA	TCG TCG TCG TCG TCG	AGF	Acc
F1	64 F1	Š.	ฮ	В				н	Ė	ģ				
	ž.	ĕ.	TCA ACA	TCG ACG	AGT	390		. 03	ã.	်ပ္ပ	5	8	AGT AGT	ğ
Ø	2	Ę.	H	ĕ	4	. 4		c)	CT	, E	OTA TER TCA	Ore ree ree	5	AGC AGC
ß.	E E	Ē	_					>	£	9	5	. 6	~	*
H	Ş	N.	AC.	ACG				30	5	5	6	6		
4	T.	Ę.						14	20	35				
9	GGT	98	ğ	989				M	167	3	_			
,	ğ	ÿ	Ď	ě	AGT	AGC .		ú	Ē.	200	5	CTC	CT	g.
ŧ	5	ģ	GCA GCA TCA GGA	000 DOG 100 DOG	~	~		U	GGT	9	GGA CIT	369 crc		
	D .	ņ	S S	6				M	3	30	J.	9		
'	ŏ	ŏ	ĕ	g.			61	Ο.	3	ğ	ş	90		
	Ö	Ö							ō	X	8	Ö		

н	TT	PIL	E.	OTC	CEA	CTG
34	te tick care and got con the accepte tick confidentisation has not for the tax tha	one are soc the and and are for oac are are are are the test the tac fire	Ęŧ		4	2
N N N N N N N N N N N N N N N N N N N	1	110	TCA CIT	CO CTC	AGT CTA	AGC CTG
03	P.	30E	e.	P	~	<
z.	33.7	7				
×	3	AAG				
4	135	8	3	B.C.G		
A	2	2				
A	E.	GAC		en.		
ø	50	990	60	TCG 000	-	Ų
- 00	Ş	ace.	Q	ğ	AGT	AGC
19	MET	KEC		_		
Đ	Sec.	9	ğ	2		
	L	34				
ps	19	980	9	200 0		
ij,	9	300	ğ	90	i. E	
#4	3	AAG				
ş.	L	oge.	CAS GUA	9		
, m	6	DOL B	20	PCG GTG	D	Age
+ 11	Ė	-64		-	~	_

					4						,			
H	caa ata aat tot tta egf got gaa gat acpoor git tat tat tot got got gat tta tla	chg arg arc teg coc ccc gas cac acc gre ste tac tec sec ccc ccc cac etg teg	CIT CIT	CTC-CTC	CTA CTA	CTG CTG	•		FI	r.	₫.	ė	VGT.	90
ы	Į.	TTG	Ü	S	U	Ů.		40	ğ	ğ	O.	7	AGT AGT	AGC AGC
n	63.7	340		_				£Q.	E O	Ę,	ğ	40	ž	ž
M	302	Š.	GCA CGA	මෙය පයල				٥	L	D.	QT.	STC		
~	g	ğ	Ö	8					į.	g	ð	ğ		••
u	Ę	ည္ည							¥	Š	GGA ACA CTT GTA ACA GTA TCA TCA	ggg acg ctc gtg acg gtg teg teg		
۶,	6	Ď.						•	5	. 5	6	0	ď.	cont.c
þe	A.T.	Š							1	13	g	£	۵	. 0
>	. E	Ę.	Y.Y.	2				Ħ	ACT	ACC	Ş	ŊĊ.		
æ	5	g	<u>g</u> .	ŝ				ø	367	380	663	99		
£4	Ü	g	ACA GEN GTA	ACG GOG GTG				¢	7	3.6				
۵	N.T.	2						ø	6	ပွဲ	gg	990		
64	17	386						· 2±	8	99	Ü	٠		
<	6	8	ð	8					e e	F				
œ	E I	Ę.	5	55				124	ర	5				
.3	5	g	Đ	Ď.	4	Ŋ.		U	50	98	8	8		
70	E	E.	TCA CIT CGA GCA	שכם כשכ במם סכם	AGT CEA	AGC CTG		κ.	G.	20	GCA GTA GCA GGA	ğ		
V.	2	ě	ğ	ğ	2	×			4	Ü	5	Ď		
27	Ž	ž						5	6	6	6	5		
×	ATA	ATG						4	GC5	9	ğ	අද්ය අඳුල අයේ අයේ		
ġ.	S	20					121	н	Aft get cit get bot eat tea gge caa got act ita oft act cit yes	ato sec ore see cae tes see cae cas see ace tro sto ace ore tec tec				
												•		

101